• How Near-Death Stress Can Seed Metastatic States

  2026-09-28

  Conod and colleagues report that a subset of colon cancer cells surviving an impending cell-death experience can acquire stable prometastatic properties, termed PAMEs, and form distant metastases in vivo. Their findings connect ER stress and cellular reprogramming to a cytokine-driven tumor-cell ecosystem, offering a framework for investigating how prometastatic states emerge before dissemination.

• Berberine, SIRT6–AMPK, and Atrial Fibrillation

  2026-09-27

  The study links impaired SIRT6–AMPK signaling with NLRP3 inflammasome activity in atrial fibrillation and reports that berberine reduces angiotensin II-induced atrial remodeling in mice. Genetic manipulation of SIRT6 supports a role for this pathway in berberine’s effects, although the findings remain preclinical and do not establish clinical efficacy.

• BQCA: Reading M1 Signaling Beyond Potency

  2026-09-26

  Benzyl Quinolone Carboxylic Acid (BQCA) is more than an M1 receptor amplifier: its effects depend on ligand concentration, assay context, and downstream signaling. Explore how recent GRK findings can sharpen experimental interpretation without overstating implications for cognition or Alzheimer’s disease.

• ER-Targeted Peptide Assembly Modulates Cancer Cell Fate

  2026-09-25

  The study combines alkaline-phosphatase-instructed peptide self-assembly with an ER-targeting group to concentrate assemblies in cancer-cell endoplasmic reticulum. This organelle-directed approach selectively induces ER stress, apoptosis, and necroptosis, and lowers the reported IC50 by more than twofold versus EISA without ER targeting.

• Oxaliplatin A8648: Practical Assay Design

  2026-09-25

  A scenario-driven guide to using Oxaliplatin (SKU A8648) in cell viability, cytotoxicity, and DNA-damage studies. It covers practical compound handling, dose-response interpretation, resistance-model limitations, and criteria for selecting a research-grade source.

• D-Luciferin Sodium Salt for CAR-M Assay Design

  2026-09-24

  D-Luciferin sodium salt supports firefly luciferase readouts, but interpreting signal in engineered macrophage studies requires more than counting photons. This article connects assay chemistry with recent CAR-macrophage research to help distinguish reporter output from cell number, metabolic state, and immune function.

• Catalpol in Cell Viability and Proliferation Assays

  2026-09-24

  A practical guide to designing and interpreting Catalpol cell-based experiments, from concentration selection and stock handling to proliferation readouts and vendor evaluation. It connects the N1352 product specifications with ischemic stroke evidence while distinguishing assay findings from disease-model conclusions.

• Ferulic Acid and ER Stress in Chemotherapy-Induced POI

  2026-09-23

  A 2026 study reports that ferulic acid protects ovarian function in cyclophosphamide-induced premature ovarian insufficiency models, with evidence linking its effects to reduced oxidative and endoplasmic reticulum stress. The findings position the PERK/eIF2α/ATF4/CHOP pathway as a candidate mechanism for further investigation, while remaining preclinical rather than evidence of clinical efficacy.

• G007-LK Tankyrase 1/2 Inhibitor Workflow

  2026-09-23

  G007-LK connects direct TNKS1/2 enzyme inhibition with practical Wnt/β-catenin and Hippo/YAP pathway assays. This workflow helps researchers distinguish β-catenin degradation induction, proliferation effects, and context-dependent responses in APC-mutant colorectal cancer and hepatocellular carcinoma models.

• Beyond the Tag: V5 as a Translational Control

  2026-09-22

  The V5 Epitope Tag Peptide is more than a detection reagent: its defined sequence provides a controllable interface for antibody binding, assay standardization, and dynamic protein research. This article connects the GKPIPNPLLGLDST peptide with single-molecule antibody screening and practical translational strategy.

• Light-Inducible RNA Release for Gene Therapy Control

  2026-09-22

  This 2026 Trends in Biotechnology study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls translational initiation in mammalian cells and therapeutic tissues. The platform combines compact post-transcriptional regulation with AAV-compatible delivery, enabling light-dependent control of obesity-related and retinal gene therapies.

• 10058-F4: Assay Design for c-Myc Biology

  2026-09-21

  10058-F4 is a c-Myc-Max dimerization inhibitor for resolving transcriptional control, mitochondrial apoptosis, and model-specific cancer phenotypes. This guide connects inhibitor mechanism with APEX2–TERT findings to improve assay interpretation without overstating causality.

• RIPA Lysis Buffer Strong for PDAC Protein Workflows

  2026-09-21

  RIPA Lysis Buffer Strong enables rigorous protein extraction for PDAC studies, but its value depends on matching detergent strength to the biological question. This guide connects buffer chemistry with CTCF–FLG-AS1–IGF2BP2 signaling and practical assay decisions.

• METTL17 Links Mitochondrial Translation to CRC Ferroptosis

  2026-09-20

  This 2024 Redox Biology study identifies METTL17 as a mitochondrial regulator of ferroptosis resistance and colorectal cancer progression. Its findings connect mitochondrial RNA methylation and translation with lipid peroxidation, providing a mechanistic basis for combining METTL17 suppression with ferroptotic stress in experimental CRC models.

• Temozolomide as a Strategic DNA-Repair Probe

  2026-09-19

  Temozolomide is more than a routine cytotoxic control: it is a mechanistically defined DNA-damage challenge that can reveal how genotype, chromatin state, and signaling dependencies shape treatment response. This thought-leadership guide connects Temozolomide handling with ATRX-aware glioma research, combination testing, and translational decision-making. Anchored by findings that ATRX-deficient high-grade glioma cells show increased sensitivity to RTK and PDGFR inhibitors and pronounced toxicity when those agents are combined with Temozolomide, the article outlines how researchers can turn a familiar cancer model drug into a sharper tool for DNA repair mechanism research and chemotherapy resistance studies.

8540 records 1/570 page Next 12345 下5页 Last page